Dissecting the non-mutational mechanisms of benign-to-malignant transition in colon cancer - the purpose of this proposal is to elucidate the rate-limiting non-mutational events underlying benign to…

Active Grant Awarded

Award ID
R01CA307963
Recipient
Awarding agency
Obligated
$704,182

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 9% complete
Place of performance
Cold Spring Harbor, NY 11724, USA

Award details come from USAspending.gov.

About this award

Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Cold Spring Harbor Laboratory a $704,182 grant on June 16, 2026, under Cancer Biology Research (CFDA 93.396), to elucidate the non-mutational events that drive benign-to-malignant transition in colorectal cancer. The $704,182 is fully obligated. The project builds a mouse model that reproduces the stepwise mutation sequence of human colorectal cancer in the distal colon: APC knockout initiates benign polyps, and KRAS G120 and TRP53 loss are then induced in rare cells of established polyps with spatial and temporal precision. Preliminary spatial transcriptomics reported that KRAS G120 reduces homeostatic regeneration signatures and induces a fetal intestinal-like stem cell state. The period of performance runs from the June 16, 2026 award date to an ultimate completion date of May 31, 2031. Work is performed at Cold Spring Harbor, NY 11724.

Sanford Burnham Prebys Medical Discovery Institute is the sub-grantee under sub-award R01CA307963-34480114, dated August 18, 2026. Its principal investigator will oversee molecular and statistical data analyses, and a graduate student will analyze single-cell and single-nuclei RNA/ATAC-Seq data, including spatial transcriptomics data the project may generate and that is publicly available from human and mouse specimens. The analyses cover gene regulatory network reverse-engineering, cellular state identification, master regulator proteins, cell type deconvolution, trajectory inference, and ligand-receptor interactions.

Description

Dissecting the non-mutational mechanisms of benign-to-malignant transition in colon cancer - the purpose of this proposal is to elucidate the rate-limiting non-mutational events underlying benign to malignant transition of colorectal cancer (CRC). Colon polyps are extremely common, occurring in up to 40% of adults over 50, and are the precursors to CRC. While the causative mutations and their stepwise acquisition in this polyp-to-C:arcinoma sequence are well understood, the non-mutational mechanisms are not. In this proposal, we will use a new mouse model that emulates, for the first lime, the stepwise acquisition of mutations in the distal colon to accurately model benign-to-malignant transition in human CRC. Benign polyps are initialed via knockout of the moat commonly mutated gene in human colon polyps (APC). The most common mutational events in advanced CRC (kras G120, TRP53 loss) are then induced in rare cells of established polyps WL1H spatial and temporal precision. In our preliminary studies, we have found 1HAT this model accurately emulates the histopathological progression of benign-to-malignant transition of human CRC, but not in mice that are lacking T C:ells-these tumors do not progress beyond adenoma. Spatial transcriptomic (S1) analyses of these tumors revealed that KRASG120 induces loss of signatures of homeostatic regeneration and gain of a fetal intestinal- like stem cell state, which is known to play a critical role in intestinal repair following injury and inflammation, KRASG120 regions within polyps were also less proliferative and depleted over time, consistent WI1H the slow cycling nature of injury-responsive stem cells in the C:olon. These findings establish that mutations, while necessary, are not sufficient to drive progression to CRC, at least when acquired in the stepwise sequence characteristic of human CRC. We hypothesize that malignant precursors in benign polyps despite having the necessary genetic mutations, require inflammatory signals to progress to cancer. These signals enable this transition by shifting the fitness landscape of the premalignant niche in favor of a fetal intestinal wound healing response over homeostatic regeneration. In aim 1, we will leverage our innovative model to functionally interrogate the role of the fetal intestinal state in benign-to-malignant transition by inducing 1H18 slate via 1) wounding or non-specific T cell activation, 2) knocking out its key transcriptional coordinator ( YAP), and 3) ablating cells in this slate. We will use ST data from the model to define the transcriptional regulatory networks underlying this state in progressing versus non-progressing lesions. In aim 2, we will identify rate-limiting microenvironmental factors that preferentially select for malignant precursor cells, and define the TRANSC11PLLONAL mechanism by which these factors cooperates with, oncogenic mutations. Results will be validated against ST data we have generated on human polyps with early malignancy. Impact: completion of !HIE proposal will provide a mechanistic foundation for understanding why some benign polyps progress to cancer while most do not. This knowledge may nominate new and mare specific biomarkers for early cancer detection, as well as rate-limiting events that could be targeted FUR cancer prevention.

Subawards

Subrecipient Amount Awarded
Sanford Burnham Prebys Medical Discovery Institute As a leader in computational analysis, SBP PI will oversee all molecular and statistical data analyses for this project, ensuring the rigorous application of… $207,028

Quick answers

Who received award R01CA307963?

R01CA307963 was awarded to Cold Spring Harbor Laboratory by National Cancer Institute (National Institutes of Health) on June 16, 2026.

How much is award R01CA307963 worth?

$704,182 has been obligated on R01CA307963.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award